Similar articles

• New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications.

  Assmann T, Ruzicka T. Assmann T, et al. Clin Dermatol. 2002 Sep-Oct;20(5):505-14. doi: 10.1016/s0738-081x(02)00271-7. Clin Dermatol. 2002. PMID: 12435521 Review. No abstract available.
• The role of the pharmaceutical industry in drug development in dermatology.

  Cauwenbergh G. Cauwenbergh G. Clin Dermatol. 2002 Sep-Oct;20(5):467-73. doi: 10.1016/s0738-081x(02)00276-6. Clin Dermatol. 2002. PMID: 12435516 Review. No abstract available.
• Psychotropic and neurotropic agents in dermatology: unapproved uses, dosages, or indications.

  Koo JY, Ng TC. Koo JY, et al. Clin Dermatol. 2002 Sep-Oct;20(5):582-94. doi: 10.1016/s0738-081x(02)00267-5. Clin Dermatol. 2002. PMID: 12435529 Review. No abstract available.
• Dapsone: unapproved uses or indications.

  Wolf R, Tüzün B, Tüzün Y. Wolf R, et al. Clin Dermatol. 2000 Jan-Feb;18(1):37-53. doi: 10.1016/s0738-081x(99)00093-0. Clin Dermatol. 2000. PMID: 10701085 Review. No abstract available.
• Miscellaneous treatments, I: sulfasalazine and pentoxifylline: unapproved uses, dosages, or indications.

  Wolf R, Matz H, Orion E, Tüzün B, Tüzün Y. Wolf R, et al. Clin Dermatol. 2002 Sep-Oct;20(5):531-46. doi: 10.1016/s0738-081x(02)00270-5. Clin Dermatol. 2002. PMID: 12435524 Review. No abstract available.